[1]
Merskey, H.; Bogduk, N. Classification of chronic pain, descriptions of chronic pain syndromes and definitions of pain terms, 2nd ed; Iasp Press: Seattle, 1994.
[2]
Stannard, C.F.; Booth, S. Churchill’s Pocketbook of Pain 2nd ed. Churchill; Livingstone, 1998.
[22]
European Medicines Agency (EMEA). Evaluation of Medicines for
Humen Use Community herbal monograph on Urtica dioca L. and
Urtica urens L. Herba. Doc. 2008. Ref. EMEA/HMPC/170261/2006
[23]
Domínguez, J.A. Contribuciones a la Materia Médica Argentina. Peuser. , 1982. Buenos Aires, Argentina
[24]
Yonathan, M.; Asres, K.; Assefa, A.; Bucar, F. In vivo antiinflammatory
and anti-nociceptive activities of Cheilanthes farinosa. J. Ethnopharmacol., 2006, 108, 462-70. [doi:10.1016/j.jep.2006.06.006]
[29]
Clark, R.A. Cutaneous tissue repair: basic biologic considerations. I. J. Am. Acad. Dermatol., 1985, 13, 701-725.
[30]
Stadelmann, W.K.; Digenis, A.G.; Tobin, G.R. Physiology and healing dynamics of chronic cutaneous wounds. Am. J. Surg., 1998, 176, 26S-38S.
[35]
Guzik, T.J.; Korbut, R.; Adamek-Guzik, T. Nitric oxide and superoxide in inflammation and immune regulation. J. Physiol. Pharmacol., 2003, 54, 469-487.
[36]
Zamora, R.; Vodovotz, Y.; Billiar, T.R. Inducible nitric oxide synthase and inflammatory diseases. Mol. Med., 2000, 6, 347-373.
[38]
Remick, D.G.; Strieter, R.M.; Eskandari, M.K.; Nguyen, D.T.; Genord, M.A.; Raiford, C.L.; Kunkel, S.L. Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Am. J. Pathol., 1990, 136, 49-60.
[48]
Chen, J.; Xie, H.; Chen, D.; Yu, B.; Mao, X.; Zheng, P.; Yu, P.; Luo, Y.; Luo, J.; He, J. Chlorogenic acid improves intestinal development via suppressing Mucosa inflammation and cell apoptosis in Weaned Pigs. ACS Omega, 2018, 3, 2211-2219.
[51]
Nogueira-Machado, J.A.; de Oliveira Volpe, C.M. HMGB-1 as a target for inflammation controlling. Recent Pat. Endocr. Metab. Immune Drug Discov., 2012, 6, 201-209.
[62]
Chen, W.P.; Wu, L.D. Chlorogenic acid suppresses interleukin-1β-induced inflammatory mediators in human chondrocytes. Int. J. Clin. Exp. Pathol., 2014, 7, 8797-8801.
[68]
Saitou, K.; Ochiai, R.; Kozuma, K.; Sato, H.; Koikeda, T.; Osaki, N.; Katsuragi, Y. Effect of chlorogenic acids on cognitive function: A randomized, double-blind, placebo-controlled trial. Nutrients, 2018, 10, 1337.
[72]
Burgos-Morón, E.; Calderón-Montaño, J.M.; Orta, M.L.; Pastor, N.; Pérez-Guerrero, C.; Austin, C.; López-Lázaro, M. The coffee constituent chlorogenic acid induces cellular DNA damage and formation of topoisomerase I-and II-DNA complexes in cells. J. Agric. Food Chem., 2012, 60, 7384-7391.
[73]
Du, W.Y.; Chang, C.; Zhang, Y.; Liu, Y.Y.; Sun, K.; Wang, C.S.; Wang, M.X.; Liu, Y.; Wang, F.; Fan, J.Y. High-dose chlorogenic acid induces inflammation reactions and oxidative stress injury in rats without implication of mast cell degranulation. J. Ethnopharmacol., 2013, 147, 74-83.
[74]
Olthof, M.R.; Hollman, P.C.; Zock, P.L.; Katan, M.B. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. Am. J. Clin. Nutr., 2001, 73, 532-538.
[77]
Barahuie, F.; Hussein, M.Z.; Arulselvan, P.; Fakurazi, S.; Zainal, Z. Controlled in vitro release of the anticancer drug chlorogenic acid using magnesium/aluminium-layered double hydroxide as a nanomatrix. Sci. Adv. Mater., 2016, 8, 501-513.
[90]
Kim, H.; Song, M.J. Oral traditional plant-based therapeutic applications for pain relief recorded in North Jeolla province, Korea. Indian J. Tradit. Knowl., 2013, 12, 4, 573-584.
[100]
Bennett, G.J.; Xie, Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain, 1988, 33, 87-107.
[106]
Malan, T.P.; Mata, H.P.; Porreca, F. Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. Anesthesiology, 2002, 96, 1161-1167.
[120]
Du, X.; Gamper, N. Potassium channels in peripheral pain pathways: Expression, function and therapeutic potential. Curr. Neuropharmacol., 2013, 11, 621-640.
[132]
Dion, C.; Haug, C.; Guan, H.; Ripoll, C.; Spiteller, P.; Coussaert, A.; Boulet, E.; Schmidt, D.; Wei, J.; Zhou, Y.; Lamottke, K. Evaluation of the anti-inflammatory and antioxidative potential of four fern species from China intended for use as food supplements. Nat. Prod. Commun., 2015, 10, 597-603.
[139]
Bukhari, I.A.; Dar, A.; Khan, R.A. Antinociceptive activity of methanolic extracts of St. John’s Wort (Hypericum perforatum) preparation. Pak. J. Pharm. Sci., 2004, 17, 13-19.
[140]
Subhan, F.; Khan, M.; Ibrar, M. Nazar-ul-Islam, Khan, A.; Gilani, A.H. Antagonism of antinociceptive effect of hydro-ethanolic extract of Hypericum perforatum Linn. by a non selective opioid receptor antagonist, naloxone. Pak. J. Biol. Sci., 2007, 10, 792-796.
[142]
Viana, A.F.; Heckler, A.P.; Fenner, R.; Rates, S.M.K. Antinociceptive activity of Hypericum caprifoliatum and Hypericum polyanthemum (Guttiferae). Braz. J. Med. Biol. Res., 2003, 36, 631-634.